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Reduction in urinary excretion of neutrophil
gelatinase-associated lipocalin by angiotensin
receptor blockers in hypertensive patients
Sir,
We recently read a paper published by Bolignano et al.w h o
investigated the association between urinary levels of neu-
trophil gelatinase-associated lipocalin (Ngal) and severity
of renal disease in proteinuric patients [1]. Urinary Ngal
is largely and rapidly increased during courses of acute
kidney injury (AKI), making it especially useful for early
diagnosis of AKI [2–5], but its clinical impact on chronic
kidney disease (CKD) remains elusive. They studied non-
diabetic patients having >1 g/day of proteinuria at least
for 6 months and also healthy subjects, and reported that
urinary Ngal concentrations were significantly associated
with the extent of proteinuria, and inversely with the esti-
mated glomerular filtration rate. The group also revealed
in another study that the elevated urinary Ngal level was a
predictor of CKD progression [6].
Our team has also evaluated the correlation between uri-
nary Ngal levels and clinical parameters in CKD patients
and observed similar findings. Since the response of uri-
nary Ngal levels to treatment has not been analysed well,
here we carried out a prospective observational study. We
chose a cohort of 26 hypertensive patients having either
Fig. 1. Urinary Ngal and albumin levels in hypertensive patients having
either obesity or diabetes. (A) Mean (±SEM) urinary Ngal/urinary creati-
nine ratios (uNgal/Cr) in patients before and 3 monthsafter treatment with
angiotensin receptor blockers, as well as in healthy controls. Comparison
was carried out by paired and unpaired t-tests. (B) No significant corre-
lation was observed between urinary Ngal and urinary albumin excretion
(uAlb/Cr)beforethetreatmentin patientswith hypertension(opencircles,
n = 26), when analysed with or without healthy controls (closed circles,
n = 10), by linear regression analysis.
diabetes (n = 2), obesity (15) or both (9), and treated
them with angiotensin receptor blockers (ARBs). They in-
cluded 15 males and 11 females who had ages of 55.5 ±
3.0 years (mean ± SEM), body mass index of 32.8 ±
1.2 kg/m2, serum creatinine of 0.82 ± 0.06 mg/dl and es-
timated glomerular filtration rate of 79.1 ± 6.5 ml/min/
1.73 m2 (calculated by a Japanese formula revised in year
2009[7]).Tenhealthyvolunteerswerealsostudied:6males
and 4 females with a mean age of 55.7 years. Clinical pa-
rameters including urinary Ngal were examined before and
3 months after initiation of the treatment. Hypertension
was defined as systolic blood pressure (BP) ≥ 140, dias-
tolic BP ≥ 90 mmHg or taking antihypertensive reagents.
Diabetes was determined as blood HbA1c level ≥6.5%.
Subjects with a body mass index ≥25 kg/m2 were con-
sidered obese. Patients neither took any other inhibitors of
the renin–angiotensin system, nor were given altered oral
regimen during the course. ARBs were chosen from can-
desartan 12 mg, olmesartan 20 mg or telmisartan 40 mg by
the treating physician’s preference (n = 14, 7 or 5, respec-
tively). The study was carried out in subjects followed at
outpatient clinics of Kyoto University Hospital and Kyoto
Medical Center, and was approved by ethical committees
in those institutes. Patients gave written informed consent.
Before administration of ARBs, hypertensive patients
had significantly elevated urinary Ngal levels as compared
to healthy controls (Figure 1A). After 3 months of treat-
ment, mean BP was reduced from 158 ± 3/92 ± 2 to 143 ±
2/82 ± 2 mmHg (n = 26, P < 0.001). All three ARBs simi-
larly decreased systolic and diastolic BP by ∼10% (supple-
mentary Table S1). At the same time, urinary excretion of
both Ngal and albumin was decreased by 36% (Figure 1A)
and 46%, respectively. A similar trend was observed when
patients were divided into ones having normoalbuminuria,
microalbuminuria or macroalbuminuria (n = 14, 6 or 6, re-
spectively; supplementary Table S2). Of note, urinary Ngal
and albumin concentrations before ARB treatment were
not significantly correlated with each other (Figure 1B,
P > 0.05), suggesting that these two measurements may
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reflect independent aspects of renal disorders, especially
when the level of proteinuria is not very severe.
To our knowledge, this is the first report to show that
short-term administration of ARBs significantly reduced
urinary Ngal levels in human subjects. Consistently, we
have recently observed that ARBs suppressed urinary ex-
cretion of Ngal in diabetic mice induced by streptozotocin
(STZ) [8]. The concentrations of Ngal were much higher
in STZ diabetic mice than human subjects investigated in
this study, which may be explained by the difference in the
extentofhyperglycaemiaandbythespeciesdifferencecon-
cerning Ngal protein metabolism. Furthermore, the treat-
ment of nephrotic patients with steroids and other immune
suppressants immediately reduced urinary Ngal excretion
[8]. These findings warrant intensive research concerning
usefulness of urinary Ngal as a monitoring marker of CKD.
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Reply
Sir,
We have read with great interest the results published by
Kasahara and co-workers, which confirm that NGAL is
becoming more than a promising biomarker of acute renal
injury.
Various human studies confirmed the utility of NGAL
dosage for the stratification of AKI risk after procedures,
potentiallydetrimentaltothekidney.Moreover,itisdemon-
strated that NGAL plays a role in the onset and progression
of chronic kidney disease [1].
Nevertheless, we think that the most interesting NGAL
future application could be represented by the evaluation
of this marker in response to different acute and chronic
therapies. Recently, our group described a strong reduction
in urinary NGAL levels in patients affected by steroid-
resistant nephrotic syndrome treated with high doses of
human immunoglobulins; this reduction was observed im-
mediately after intravenous Ig administration and persisted
even 24 h later [2].
Ifconfirmedindifferentsituations,theseearlyvariations
in NGAL levels could help to predict the effectiveness of
different therapeutical approaches, in order to personalize
the treatment of nephropatic patients.
Kasahara and co-workers did not describe any relation-
ship between NGAL urinary excretion and albuminuria.
Nevertheless,inarecentstudyconductedon56diabeticpa-
tients classified according to glomerular damage (normo-,
micro- and macroalbuminuria), NGAL levels directly cor-
related with the severity of the glomerular impairment and
they were higher innormoalbuminuric patients than incon-
trols[3];thesefindingssuggestaparallelismbetweentubu-
lar impairment and glomerular damage and a potential role
for NGAL as a marker of diabetic nephropathy even earlier
than microalbuminuria.
Enlarging the group of patients affected by arterial hy-
pertension enrolled in the study, we wonder if Kasahara
et al. may extend their observations also to this pathologic
condition, which significantly involves the renal tubule.
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